Technology | August 06, 2013

FDA Clears Philips Healthcare's Pinnacle³ Proton Treatment Planning System

The system supports treatment planning for multiple delivery devices, accelerates time to first clinical treatment

August 6, 2013 — Philips Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Pinnacle³ Proton treatment planning system.

Philips’ Pinnacle³ is a treatment planning system for external beam radiotherapy, which provides accuracy and reliability to users independent of the treatment delivery system. The Proton module is fully integrated into the Pinnacle³ planning environment and continues to offer personalized user experience. 

"The transition for an existing and well-established photon center, to planning protons, is nicely facilitated by the Pinnacle³ system, whether it’s for proton-only planning, or combination planning of photons and protons. This capability has allowed us to confidently choose the best treatment modality for each patient," said Eric E. Klein, M.D., professor of radiation oncology, Washington University in St. Louis, Mo.

Designed through extensive clinical collaboration with current proton treatment centers, the Pinnacle³ proton module addresses some of the major challenges faced within proton planning today. The combination of specially designed tools and the seamless integration within Pinnacle³ provides an extensive range of functionalities that include composite proton-photon planning, fast commissioning and automated contouring and re-planning.  These features offer clinicians the chance to select the appropriate treatment options for the patient and do the work quickly through improved workflow.

Features like automated re-planning allow the clinicians to adapt the treatment plans quickly (which, in turn, allow them to change the treatment regime) and take into account the impact of the treatment on the patient’s anatomy, providing more targeted treatments. Without these automation tools, the task remains very laborious and time-consuming; deterring clinicians from developing alternative treatment plans.

The number of centers treating patients with proton therapy is steadily increasing. With the introduction of more cost-effective treatment machines, which are reducing the investment cost of starting a proton center, the number of new programs under development is rising rapidly. Many of these centers see themselves as pioneers that advance the possibilities to provide improved care for cancer patients.

The system received FDA clearance in August 2013.

For more information: www.healthcare.philips.com

 

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
RaySearch Launches RayCare Oncology Information System

Image courtesy of RaySearch Laboratories

Technology | Oncology Information Management Systems (OIMS) | December 22, 2017
RaySearch announced the first release of RayCare, a new oncology information system (OIS) designed to connect the...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Overlay Init